Dr Fook Hong and colleagues from China investigated the management and outcome of patients with peptic ulcer/erosion-related aspirin and clopidogrel cotherapy.
The team analyzed 106 patients with endoscopically proven peptic ulcers/erosions after receiving cotherapy from 2002 to 2006.
Ulcers/erosions developed in 27 patients during hospitalization for cardiac events, and in 79 patients after hospital discharge.
Of 27 patients hospitalized for acute cardiac events, gastrointestinal bleeding and dyspepsia occurred in 24 and 3, respectively.
The team found the most common lesion was gastric ulcer.
|Bleeding occurred in 64 of 79 patients|
|Journal of Gastroenterology|
Of 79 discharged patients, gastrointestinal bleeding and dyspepsia occurred in 64 and 15, respectively.
The most common bleeding and dyspeptic lesions were gastric ulcer and gastritis, respectively.
Overall, 17 patients underwent endoscopic hemostasis all successfully. aspirin and clopidogrel cotherapy was continued in 57 patients for a median of 3 months.
Most were coprescribed a proton pump inhibitor.
The research team did not observed recurrent gastrointestinal bleeding.
Dr Hong's team concluded, “After aspirin and clopidogrel cotherapy cotherapy, gastric ulcer or gastritis were the most common endoscopic lesions.”
“The combination of a proton pump inhibitor and endoscopic treatment for ulcer bleeding was highly successful.”
“After patient stabilization, continuation of aspirin and clopidogrel cotherapy with a proton pump inhibitor appears to be safe.”